Enanta Pharmaceuticals Earnings Estimate

ENTA Stock  USD 8.22  0.27  3.18%   
The next projected EPS of Enanta Pharmaceuticals is estimated to be -1.175 with future projections ranging from a low of -1.42 to a high of -1.06. Enanta Pharmaceuticals' most recent 12-month trailing earnings per share (EPS TTM) is at -4.95. Please be aware that the consensus of earnings estimates for Enanta Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Yuan Drop
 
Covid
Enanta Pharmaceuticals is projected to generate -1.175 in earnings per share on the 31st of March 2025. Enanta Pharmaceuticals earnings estimates show analyst consensus about projected Enanta Pharmaceuticals EPS (Earning Per Share). It derives the highest and the lowest estimates based on Enanta Pharmaceuticals' historical volatility. Many public companies, such as Enanta Pharmaceuticals, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Enanta Pharmaceuticals' earnings estimates, investors can diagnose different trends across Enanta Pharmaceuticals' analyst sentiment over time as well as compare current estimates against different timeframes. The current year's Gross Profit is expected to grow to about 102.6 M, whereas Pretax Profit Margin is projected to grow to (1.90).
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.

Enanta Pharmaceuticals Earnings Estimation Breakdown

The calculation of Enanta Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Enanta Pharmaceuticals is estimated to be -1.175 with the future projection ranging from a low of -1.42 to a high of -1.06. Please be aware that this consensus of annual earnings estimates for Enanta Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
-1.05
-1.42
Lowest
Expected EPS
-1.175
-1.06
Highest

Enanta Pharmaceuticals Earnings Projection Consensus

Suppose the current estimates of Enanta Pharmaceuticals' value are higher than the current market price of the Enanta Pharmaceuticals stock. In this case, investors may conclude that Enanta Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Enanta Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of March 2025Current EPS (TTM)
776.47%
-1.05
-1.175
-4.95

Enanta Pharmaceuticals Earnings per Share Projection vs Actual

Actual Earning per Share of Enanta Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Enanta Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Enanta Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Enanta Pharmaceuticals Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Enanta Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Enanta Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.

Enanta Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Enanta Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2025-02-05
2024-12-31-1.3525-1.050.302522 
2024-11-18
2024-09-30-0.92-1.36-0.4447 
2024-08-05
2024-06-30-1.45-1.070.3826 
2024-05-06
2024-03-31-1.33-1.47-0.1410 
2024-01-26
2023-12-31-1.19-1.58-0.3932 
2023-11-20
2023-09-30-2.15-1.330.8238 
2023-08-07
2023-06-30-2.34-1.860.4820 
2023-05-08
2023-03-31-1.98-1.790.19
2023-02-07
2022-12-31-1.59-1.390.212 
2022-11-21
2022-09-30-1.35-1.270.08
2022-08-08
2022-06-30-1.39-1.53-0.1410 
2022-05-09
2022-03-31-1.43-1.63-0.213 
2022-02-08
2021-12-31-1.08-1.48-0.437 
2021-11-22
2021-09-30-1.22-1.220.0
2021-08-05
2021-06-30-1.28-1.190.09
2021-05-06
2021-03-31-0.98-1.09-0.1111 
2021-02-08
2020-12-31-0.74-0.410.3344 
2020-11-23
2020-09-30-0.95-1.46-0.5153 
2020-08-04
2020-06-30-0.84-0.710.1315 
2020-05-06
2020-03-31-0.89-0.30.5966 
2020-02-06
2019-12-310.550.650.118 
2019-11-21
2019-09-300.530.44-0.0916 
2019-08-06
2019-06-300.160.330.17106 
2019-05-07
2019-03-31-0.080.20.28350 
2019-02-06
2018-12-311.351.25-0.1
2018-11-26
2018-09-301.191.30.11
2018-08-07
2018-06-300.980.97-0.01
2018-05-08
2018-03-310.530.610.0815 
2018-02-07
2017-12-310.190.590.4210 
2017-11-20
2017-09-302.131.86-0.2712 
2017-08-07
2017-06-30-0.48-0.440.04
2017-05-08
2017-03-31-0.38-0.280.126 
2017-02-08
2016-12-31-0.18-0.26-0.0844 
2016-11-21
2016-09-30-0.14-0.090.0535 
2016-08-08
2016-06-30-0.09-0.060.0333 
2016-05-09
2016-03-310.1-0.09-0.19190 
2016-02-08
2015-12-311.131.360.2320 
2015-11-23
2015-09-300.150.290.1493 
2015-08-06
2015-06-300.190.13-0.0631 
2015-05-07
2015-03-311.761.49-0.2715 
2015-02-05
2014-12-313.822.18-1.6442 
2014-11-24
2014-09-30-0.33-0.270.0618 
2014-08-11
2014-06-301.671.820.15
2014-05-12
2014-03-310.08-0.28-0.36450 
2014-02-13
2013-12-31-0.29-0.3-0.01
2013-11-25
2013-09-30-0.29-0.250.0413 
2013-08-12
2013-06-30-0.33-0.230.130 
2013-05-08
2013-03-31-0.33-2.28-1.95590 

About Enanta Pharmaceuticals Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Enanta Pharmaceuticals earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Enanta Pharmaceuticals estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Enanta Pharmaceuticals fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-290.7 M-276.2 M
Retained Earnings Total Equity-84.2 M-79.9 M
Earnings Yield(0.61)(0.58)
Price Earnings Ratio(2.17)(2.06)
Price Earnings To Growth Ratio 0.12  0.13 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Enanta Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enanta Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enanta Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enanta Pharmaceuticals Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. If investors know Enanta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enanta Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.66)
Earnings Share
(4.95)
Revenue Per Share
3.142
Quarterly Revenue Growth
(0.06)
Return On Assets
(0.18)
The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enanta Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enanta Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enanta Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.